

Bahriye Aktas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5016526/publications.pdf>

Version: 2024-02-01

135
papers

5,011
citations

147801

31
h-index

95266

68
g-index

143
all docs

143
docs citations

143
times ranked

5953
citing authors

#	ARTICLE	IF	CITATIONS
1	Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R46.	5.0	658
2	HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 403-412.	2.5	330
3	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSeptoâ€”GBC 69): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 345-356.	10.7	316
4	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. <i>Journal of Clinical Oncology</i> , 2016, 34, 2341-2349.	1.6	246
5	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. <i>Breast Cancer Research</i> , 2009, 11, R59.	5.0	217
6	Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 581-590.	2.5	198
7	Prognostic impact of circulating tumor cells assessed with the CellSearch Systemâ„¢ and AdnaTest Breastâ„¢ in metastatic breast cancer patients: the DETECT study. <i>Breast Cancer Research</i> , 2012, 14, R118.	5.0	160
8	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 573-583.	2.5	149
9	Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. <i>Gynecologic Oncology</i> , 2011, 122, 356-360.	1.4	127
10	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 503-510.	2.5	118
11	[18F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 56-65.	6.4	115
12	De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)â€”Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptorâ€”Positive Phase II Randomized Trialâ€”Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. <i>Journal of Clinical Oncology</i> , 2017, 35, 3046-3054.	1.6	114
13	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1045-1052.	1.6	108
14	ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance. <i>Clinical Chemistry</i> , 2014, 60, 1282-1289.	3.2	101
15	Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 822-830.	2.5	97
16	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBC 69â€”GeparSepto. <i>Journal of Clinical Oncology</i> , 2019, 37, 2226-2234.	1.6	95
17	Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-557.	1.6	91
18	Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. <i>Journal of the National Cancer Institute</i> , 2018, 110, 628-637.	6.3	88

#	ARTICLE	IF	CITATIONS
19	Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1814-1824.	6.4	85
20	West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 799-808.	1.6	85
21	Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 522.	2.6	71
22	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	1.6	60
23	RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 1054-1062.	3.2	55
24	Correlation of Standardized Uptake Value and Apparent Diffusion Coefficient in Integrated Whole-Body PET/MRI of Primary and Recurrent Cervical Cancer. <i>PLoS ONE</i> , 2014, 9, e96751.	2.5	51
25	Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 67-76.	6.4	49
26	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2557-2567.	1.6	49
27	Cell and Nucleus Shape as an Indicator of Tissue Fluidity in Carcinoma. <i>Physical Review X</i> , 2021, 11, .	8.9	46
28	Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2017, 63, 1585-1593.	3.2	45
29	Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R71.	5.0	44
30	Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 622-629.	6.4	41
31	Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 1316-1326.	10.7	39
32	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 0, 7, 41677-41690.	1.8	36
33	Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. <i>PLoS ONE</i> , 2017, 12, e0172553.	2.5	34
34	Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. <i>Cancer</i> , 2020, 126, 4847-4858.	4.1	33
35	Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine-green (ICG). <i>Journal of Surgical Oncology</i> , 2016, 113, 554-559.	1.7	31
36	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 2047-2056.	2.5	28

#	ARTICLE	IF	CITATIONS
37	Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients. <i>European Journal of Radiology</i> , 2017, 89, 14-19.	2.6	28
38	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 93-104.	2.5	28
39	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	3.3	27
40	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. <i>International Journal of Cancer</i> , 2020, 146, 262-271.	5.1	27
41	Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as "total mesometrial resection (TMMR)" by M HÄ¶ckel translated to robotic surgery (rTMMR). <i>World Journal of Surgical Oncology</i> , 2013, 11, 211.	1.9	25
42	Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M HÄ¶ckel translated to robotic surgery. <i>World Journal of Surgical Oncology</i> , 2013, 11, 198.	1.9	25
43	Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?. <i>Scientific Reports</i> , 2016, 6, 26355.	3.3	25
44	Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1061.	1.6	25
45	Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. <i>Anticancer Research</i> , 2011, 31, 3623-8.	1.1	25
46	Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. <i>Anticancer Research</i> , 2013, 33, 329-36.	1.1	23
47	Circulating tumor cells in breast cancer. <i>Clinica Chimica Acta</i> , 2013, 423, 39-45.	1.1	22
48	Definition of Compartment Based Radical Surgery in Uterine Cancer"Part I: Therapeutic Pelvic and Periaortic Lymphadenectomy by Michael HÄ¶ckel Translated to Robotic Surgery. <i>ISRN Obstetrics & Gynecology</i> , 2013, 2013, 1-17.	1.2	20
49	Efficacy and safety of nab-paclitaxel 125mg/m2 and nab-paclitaxel 150mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBC 69). <i>Breast Cancer Research and Treatment</i> , 2017, 163, 495-506.	2.5	20
50	Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 141-149.	2.5	19
51	Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 153-160.	1.7	19
52	Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1049-1054.	1.0	18
53	The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097313.	3.2	18
54	Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. , 2021, 9, e002198.		18

#	ARTICLE	IF	CITATIONS
55	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 17307.	3.3	16
56	Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 506-506.	1.6	15
57	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128.	1.1	14
58	Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-572.	1.6	14
59	<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8581-8594.	2.8	14
60	Technique of ICG-guided Targeted Compartmental Pelvic Lymphadenectomy (TCL) combined with Pelvic Peritoneal Mesometrial Resection (PMMR) for locoregional control of endometrial cancer – A proposal. <i>Gynecologic Oncology Reports</i> , 2017, 20, 125-126.	0.6	13
61	Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2148-2158.	7.0	12
62	Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. <i>Oncology Reports</i> , 2013, 30, 441-447.	2.6	11
63	Early ovarian cancer surgery with indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, pelvic part). <i>Journal of Gynecologic Oncology</i> , 2017, 28, e68.	2.2	11
64	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4884.	3.7	11
65	Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. <i>Cancer Research</i> , 2015, 75, S2-07-S2-07.	0.9	11
66	FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo. <i>Cancers</i> , 2021, 13, 956.	3.7	10
67	Update Breast Cancer 2021 Part 1 – Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538.	1.8	10
68	Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 504-504.	1.6	10
69	First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. <i>Anticancer Research</i> , 2016, 36, 967-74.	1.1	10
70	Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 87-92.	2.5	9
71	Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer. <i>Molecular Medicine Reports</i> , 2017, 15, 2957-2968.	2.4	9
72	Surgical treatment of early ovarian cancer with compartmental resection of regional lymphatic network and indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, paraaortic) Tj ETQq0 0 0 qgBT /Overdock 10 Tf		

#	ARTICLE	IF	CITATIONS
73	Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 1032-1032.	1.6	9
74	Roadmap to Local Tumour Growth: Insights from Cervical Cancer. Scientific Reports, 2019, 9, 12768.	3.3	8
75	The Mechanical Fingerprint of Circulating Tumor Cells (CTCs) in Breast Cancer Patients. Cancers, 2021, 13, 1119.	3.7	8
76	Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. Breast Care, 2016, 11, 323-327.	1.4	7
77	Quality of life and associated factors after surgical treatment of vulvar cancer by vulvar field resection (VFR). Archives of Gynecology and Obstetrics, 2020, 302, 191-201.	1.7	7
78	An Observational Study on Breast Cancer Survival and Lifestyle Related Risk Factors. In Vivo, 2021, 35, 1007-1015.	1.3	7
79	Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. Breast Cancer Research, 2021, 23, 36.	5.0	7
80	Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system. Gynecologic Oncology Reports, 2016, 16, 24.	0.6	6
81	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. BMC Cancer, 2018, 18, 541.	2.6	6
82	Update Breast Cancer 2021 Part 2 "Advanced Stages, Long-Term Consequences and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2021, 81, 539-548.	1.8	6
83	The DETECT study concept: Individualized therapy of metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS634-TPS634.	1.6	6
84	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clinical Cancer Research, 2022, 28, 4995-5003.	7.0	6
85	The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patients. Oncology Letters, 2014, 7, 2007-2012.	1.8	5
86	CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial. BMC Sports Science, Medicine and Rehabilitation, 2021, 13, 15.	1.7	5
87	Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. International Journal of Cancer, 2021, 148, 2614-2627.	5.1	5
88	The Importance of Clinical Examination under General Anesthesia: Improving Parametrial Assessment in Cervical Cancer Patients. Cancers, 2021, 13, 2961.	3.7	5
89	Heterogeneity between Core Needle Biopsy and Synchronous Axillary Lymph Node Metastases in Early Breast Cancer Patients" A Comparison of HER2, Estrogen and Progesterone Receptor Expression Profiles during Primary Treatment Regime. Cancers, 2022, 14, 1863.	3.7	5
90	Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer. Gynecologic Oncology Reports, 2016, 18, 14.	0.6	4

#	ARTICLE	IF	CITATIONS
91	Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation. <i>Gynecologic Oncology Reports</i> , 2017, 20, 22-23.	0.6	4
92	The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. <i>Breast</i> , 2021, 59, 58-66.	2.2	4
93	Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial. , 2015, , .		4
94	Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 556-556.	1.6	4
95	Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 67-72.	0.8	4
96	Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 81-88.	2.5	3
97	Evaluation of a novel ELISA for the tumor-associated antigen CA 72â€™4 in patients with ovarian cancer. <i>Future Science OA</i> , 2016, 2, FSO145.	1.9	3
98	Surgical anatomy of the ligamentous mesometrium and robotically assisted ICG-guided resection in cervical cancer. <i>Gynecologic Oncology Reports</i> , 2017, 20, 4.	0.6	3
99	Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 504-504.	1.6	3
100	Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 573-573.	1.6	3
101	Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 573-573.	1.6	3
102	Abstract 3777: RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients. , 2017, , .		2
103	Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial. , 2020, , .		2
104	Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12102-12102.	1.6	2
105	Abstract 3076: A fully automated q-PCR-based circulating tumor cell analysis using the AlereTMq-Analyzer test platform. , 2014, , .		2
106	Abstract OT3-2-04: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. , 2015, , .		2
107	The diagnostic value of core needle biopsy in cervical cancer: A retrospective analysis. <i>PLoS ONE</i> , 2022, 17, e0262257.	2.5	2
108	Abstract 383: The AdnaCollector, a new fully automated selection for circulating tumor cells in blood of primary and metastatic breast cancer patients. <i>Cancer Research</i> , 2015, 75, 383-383.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Abstract 5010: Prediction of therapy resistance by targeted massive-parallel sequencing in primary HER2-positive breast cancer. <i>Cancer Research</i> , 2016, 76, 5010-5010.	0.9	1
110	Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1077-1077.	1.6	1
111	Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 552-552.	1.6	1
112	Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 524-524.	1.6	1
113	Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22032-e22032.	1.6	1
114	DETECT III: A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1146-TPS1146.	1.6	1
115	Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10599-10599.	1.6	1
116	Abstract 502: Gene expression signatures in circulating tumor cells are prognostic for metastatic lesions in breast cancer patients and correlate with response to therapy. <i>Cancer Research</i> , 2016, 76, 502-502.	0.9	1
117	Use of a microsurgical vascular clip system (Yasargil clip) in laparoscopic fibroid enucleation. <i>Journal of the Turkish German Gynecology Association</i> , 2020, 21, 305-307.	0.6	1
118	Current role of liquid biopsy in metastatic breast cancer and future perspectives. <i>Der Gynakologe</i> , 2016, 49, 680-684.	1.0	0
119	Postoperative non-traumatic compartment syndrome (PNCS) in gynecologic surgery. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1013-1019.	1.7	0
120	A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1141-TPS1141.	1.6	0
121	Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5575-5575.	1.6	0
122	Evaluation of risk recurrence in early breast cancer assessed by Oncotype DX and tumor cell dissemination to blood and bone marrow.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11516-e11516.	1.6	0
123	Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12007-e12007.	1.6	0
124	Abstract 3066: Establishment of a new method for the selection and detection of circulating tumor cells in metastatic breast cancer patients. , 2014, , .		0
125	Abstract P6-08-39: Influence of lifestyle factors and tumor cell dissemination in 632 early breast cancer patients. , 2015, , .		0
126	Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11555-e11555.	1.6	0

#	ARTICLE	IF	CITATIONS
127	The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).. Journal of Clinical Oncology, 2015, 33, TPS11109-TPS11109.	1.6	0
128	Abstract 372: Expression profiling of circulating tumor cells: A prognostic and predictive biomarker in metastatic breast cancer. , 2015, , .		0
129	Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO.. Journal of Clinical Oncology, 2017, 35, e12547-e12547.	1.6	0
130	Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.. Journal of Clinical Oncology, 2017, 35, 1012-1012.	1.6	0
131	Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial.. Journal of Clinical Oncology, 2017, 35, TPS5611-TPS5611.	1.6	0
132	Abstract P4-06-06: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 149 breast cancer patients - indicating tumoral heterogeneity. , 2020, , .		0
133	Abstract 4604: Can breast cancer cells be distinguished from blood cells by mechanical parameters? A label-free CTC detection approach. , 2020, , .		0
134	Abstract P2-01-16: Targeted sequencing of plasma-derived vs. urinary cfDNA from patients with triple negative breast cancer. Cancer Research, 2022, 82, P2-01-16-P2-01-16.	0.9	0
135	Update Mammakarzinom 2021 Teil 1 â€œ PrÃvention und frÃhe Krankheitsstadien. Senologie - Zeitschrift FÃ¼r Mammadiagnostik Und -therapie, 2021, 18, 377-390.	0.0	0